ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE SHEFFIELD TYPE 2 DIABETES MODEL

被引：1
|
作者：
Brennan, A. [1 ]
Gillett, M. [1 ]
Duenas, A. [1 ]
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66666-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A501 / A501
页数：1
相关论文
共 50 条
  • [1] DAPAGLIFLOZIN: COST EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN ECUADOR
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Sanchez, Solis C.
    Acosta, W.
    Solorzano, J.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2016, 19 (03) : A202 - A202
  • [2] Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
    Hara Kousoulakou
    Magdalini Hatzikou
    Varvara Baroutsou
    John Yfantopoulos
    Cost Effectiveness and Resource Allocation, 15
  • [3] Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
    Kousoulakou, Hara
    Hatzikou, Magdalini
    Baroutsou, Varvara
    Yfantopoulos, John
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [4] COST-EFFECTIVENESS OF SITAGLIPTIN COMPARED TO SULPHONYLUREA AS AN ADD-ON TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Athanasakis, K.
    Zhuo, J.
    Chen, J.
    Boubouchairopoulou, N.
    Tarantilis, F.
    Papageorgiou, M.
    Retsa, P.
    Brandtmuller, A.
    Tunceli, K.
    Karokis, A.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [5] Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
    Kovacs, Christopher S.
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : 1773 - 1788
  • [6] Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus
    Pan, C.
    Xing, X.
    Han, P.
    Zheng, S.
    Ma, J.
    Liu, J.
    Lv, X.
    Lu, J.
    Bader, G.
    DIABETES OBESITY & METABOLISM, 2012, 14 (08): : 737 - 744
  • [7] Empagliflozin as add-on to pioglitazone with or without metformin in patients with Type 2 diabetes
    Kovacs, C. S.
    Seshiah, V.
    Merker, L.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Stella, P.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 88 - 88
  • [8] COST-EFFECTIVENESS ANALYSIS OF VILDAGLIPTIN VS. GLIMEPIRIDE AS ADD-ON TO METFORMIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN GREECE
    Kousoulakou, H.
    Kalogeropoulou, M.
    Panitti, E.
    VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [9] Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes
    Brown, RR
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 : S24 - S27
  • [10] ECONOMIC EVALUATION OF VILDAGLIPTIN COMPARED TO GLIMEPIRIDE AS ADD-ON TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN GREECE
    Hatzikou, M.
    Rombopoulos, G.
    Yfantopoulos, J.
    VALUE IN HEALTH, 2012, 15 (07) : A501 - A501
12345